Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants

Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor blocking therapy on the B cell sub-populations and the cross-ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauvin, Camille, Levillayer, Laurine, Roumier, Mathilde, Nielly, Hubert, Roth, Claude, Karnam, Anupama, Bonam, Srinivasa Reddy, Bourgarit, Anne, Dubost, Clément, Bousquet, Aurore, Le Burel, Sébastien, Mestiri, Raphaële, Sene, Damien, Galland, Joris, Vasse, Marc, Groh, Matthieu, Le Marchand, Mathilde, Vassord-Dang, Camille, Gautier, Jean-François, Pham-Thi, Nhan, Verny, Christiane, Pitard, Bruno, Planchais, Cyril, Mouquet, Hugo, Paul, Richard, Simon-Loriere, Etienne, Bayry, Jagadeesh, Gilardin, Laurent, Sakuntabhai, Anavaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894676/
https://www.ncbi.nlm.nih.gov/pubmed/36776936
http://dx.doi.org/10.1016/j.isci.2023.106124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894676/
https://www.ncbi.nlm.nih.gov/pubmed/36776936
http://dx.doi.org/10.1016/j.isci.2023.106124

Ejemplares similares